×
S&P 500   3,978.73
DOW   32,120.28
QQQ   291.26
S&P 500   3,978.73
DOW   32,120.28
QQQ   291.26
S&P 500   3,978.73
DOW   32,120.28
QQQ   291.26
S&P 500   3,978.73
DOW   32,120.28
QQQ   291.26
NASDAQ:PTLA

Portola Pharmaceuticals (PTLA) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$18.03
$18.03
50-Day Range
$18.03
$18.03
52-Week Range
$5.31
$31.73
Volume
N/A
Average Volume
3.17 million shs
Market Capitalization
$1.42 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.32

Receive PTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for Portola Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Portola Pharmaceuticals logo

About Portola Pharmaceuticals

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a dual spleen tyrosine kinase and janus kinases inhibitor in development for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor that has completed Phase II clinical trial for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Millennium Pharmaceuticals, Inc.; SRX Cardio; LLC; Ora; and Astellas Pharma Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.

Headlines

Portola Pharmaceuticals, Inc. (PTLA)
Why Portola Pharmaceuticals Skyrocketed 25.6% Today
Stock Alert: Alexion Pharma Up 7%
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PTLA
Fax
N/A
Employees
324
Year Founded
N/A

Sales & Book Value

Annual Sales
$116.64 million
Book Value
$1.67 per share

Profitability

Net Income
$-290.66 million
Net Margins
-232.73%
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$1.42 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/11/2020
Today
5/26/2022

MarketRank

Overall MarketRank

1.44 out of 5 stars

Medical Sector

1074th out of 1,421 stocks

Pharmaceutical Preparations Industry

529th out of 678 stocks

Analyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -













Portola Pharmaceuticals (NASDAQ:PTLA) Frequently Asked Questions

How were Portola Pharmaceuticals' earnings last quarter?

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) posted its quarterly earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by $0.14. The biopharmaceutical company earned $26.40 million during the quarter, compared to analysts' expectations of $33.88 million. Portola Pharmaceuticals had a negative net margin of 232.73% and a negative trailing twelve-month return on equity of 267.86%. The firm's quarterly revenue was up 18.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.02) earnings per share.
View Portola Pharmaceuticals' earnings history
.

Who are Portola Pharmaceuticals' key executives?
Portola Pharmaceuticals' management team includes the following people:
  • Ms. Mardi C. Dier, Exec. VP, Chief Bus. Officer & CFO (Age 55)
  • Dr. John T. Curnutte, Exec. VP and Head of R&D (Age 67)
  • Mr. J. Scott Garland M.B.A., MBA, Pres & CEO (Age 50)
  • Cara Miller, VP of Investor Relations and Corp. Communications
  • Mr. John B. Moriarty Jr., Exec. VP, Gen. Counsel & Sec. (Age 51)
What other stocks do shareholders of Portola Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Portola Pharmaceuticals investors own include Lexicon Pharmaceuticals (LXRX), Novavax (NVAX), Iovance Biotherapeutics (IOVA), Editas Medicine (EDIT), Amarin (AMRN), Exelixis (EXEL), NVIDIA (NVDA), Geron (GERN), ACADIA Pharmaceuticals (ACAD) and Aileron Therapeutics (ALRN).

What is Portola Pharmaceuticals' stock symbol?

Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."

What is Portola Pharmaceuticals' stock price today?

One share of PTLA stock can currently be purchased for approximately $18.03.

How much money does Portola Pharmaceuticals make?

Portola Pharmaceuticals has a market capitalization of $1.42 billion and generates $116.64 million in revenue each year. The biopharmaceutical company earns $-290.66 million in net income (profit) each year or ($4.06) on an earnings per share basis.

How many employees does Portola Pharmaceuticals have?

Portola Pharmaceuticals employs 324 workers across the globe.

What is Portola Pharmaceuticals' official website?

The official website for Portola Pharmaceuticals is www.portola.com.

How can I contact Portola Pharmaceuticals?

Portola Pharmaceuticals' mailing address is 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-246-7000 or via email at [email protected].

This page was last updated on 5/26/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.